Juanita Pérez-Escobar

Dr. Juanita Pérez-Escobar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Transplantation Proceedings
Verified
Journal Article
Closed access
ERErika Faride Rodríguez-Aguilar
Erika Faride Rodríguez-Aguilar
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
DHDiana Sánchez Herrera
Diana Sánchez Herrera
MGMario García-Alanis
Mario García-Alanis
LTLiz Toapanta-Yanchapaxi
Liz Toapanta-Yanchapaxi
IGIgnacio García-Juárez
Ignacio García-Juárez

19 May 2025 in Life
Verified
Journal Article
Open access
PDF file
AHAline Huerta
Aline Huerta
MAMariana Arellano
Mariana Arellano
CCClyo Anahí Chávez-Méndez
Clyo Anahí Chávez-Méndez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
CPCarmen Palacios-Reyes
Carmen Palacios-Reyes
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease, linked closely to metabolic syndrome and rising obesity rates. Affecting up to 37% of the global adult population, MASLD prevalence is exceptionally high among individuals of Hispanic descent, with genetic factors such as the PNPLA3 gene mutation playing a significant role. The subject of this review is the traditional Mesoamerican “milpa” diet, which includes unprocessed local crops like maize, beans, pumpkins, chili, and tomatoes and may represent a strategy to combat MASLD. Current treatment recommendations emphasize weight loss; a reduced intake of saturated fats, processed meats, and added sugars; and increased physical activity. The milpa diet, rich in protein, fiber, vitamins, and bioactive compounds, aligns with these recommendations and could potentially mitigate MASLD by preventing liver fat accumulation and fibrosis. This narrative review focuses on available preclinical and clinical studies adopting the milpa diet as a culturally relevant, nutritious, and sustainable dietary approach in preventing and treating MASLD. More clinical studies are needed to develop precise nutritional quantitative recommendations and guidelines.

20 August 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
JGJosé Carlos Gasca
José Carlos Gasca
JCJesús Enrique Castrejón-Sánchez
Jesús Enrique Castrejón-Sánchez
MFMario Carrasco Flores
Mario Carrasco Flores
Enzo Vasquez JimenezEnzo Vasquez Jimenez
Enzo Vasquez Jimenez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
PCPaula Costa-Urrutia
Paula Costa-Urrutia
Background/Objectives: Acute liver failure (ALF) is a life-threatening condition with high mortality in nontransplant candidates. Therapeutic plasma exchange (TPE) has emerged as a promising intervention for removing inflammatory mediators and toxic metabolites. In Latin America, data on the efficacy of TPE in ALF patients are limited. This real-world study aimed to compare 30-day survival outcomes between patients receiving standard medical treatment (SMT) and those receiving SMT plus TPE. Methods: We analyzed 25 ALF patients admitted to the tertiary intensive care unit (ICU) of Hospital Juárez of Mexico City, Mexico, from 2018 to 2024. Patients received either standard medical treatment (SMT group, n = 12) or SMT with TPE (TPE group, n = 13), including high-volume TPE (n = 8) and standard-volume TPE (n = 5). Survival analysis was performed via Kaplan–Meier estimates, and binomial regression analysis was run to estimate the mortality probability stratified by the hepatic encephalopathy grade. Results: At 30 days, survival was significantly greater in the TPE group (92%) than in the SMT group (50%) (p = 0.02). The greatest survival benefit was observed in patients with Grade 4 encephalopathy. The ICU stay was longer in the TPE group, reflecting the complexity of ALF management. Conclusions: TPE significantly improves 30-day survival in ALF patients compared with SMT alone, supporting its role as an adjunct therapy. Further studies are needed to refine patient selection and optimize treatment protocols.

15 November 2025 in Annals of Hepatology
Verified
Journal Article
Open access
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
RVRicardo Ivan Velazquez-Silva
Ricardo Ivan Velazquez-Silva
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
JGJosé Carlos Gasca-Aldama
José Carlos Gasca-Aldama

10 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JGJosé Carlos Gasca
José Carlos Gasca
JCJesús Enrique Castrejón-Sánchez
Jesús Enrique Castrejón-Sánchez
MFMario Carrasco Flores
Mario Carrasco Flores
Enzo Vasquez JimenezEnzo Vasquez Jimenez
Enzo Vasquez Jimenez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
PCPaula Costa-Urrutia
Paula Costa-Urrutia
Background/Objectives: Acute liver failure (ALF) is a life-threatening condition with high mortality in nontransplant candidates. Therapeutic plasma exchange (TPE) has emerged as a promising intervention for removing inflammatory mediators and toxic metabolites. In Latin America, data on the efficacy of TPE in ALF patients is limited. This real-world study aimed to compare 30-day survival outcomes between patients receiving standard medical treatment (SMT) and those receiving SMT plus TPE. Methods: We analyzed 25 ALF patients admitted to the tertiary intensive care unit (ICU) of Hospital Juárez of Mexico City, Mexico, from 2018–2024. Patients received either standard medical treatment (SMT group, n=12) or SMT with TPE (TPE group, n=13), including high-volume TPE (n=8) and standard-volume TPE (n=5). Survival analysis was performed via Kaplan‒Meier estimates, and binomial regression analysis was run to estimate the mortality probability stratified by the hepatic encephalopathy grade. Results: At 30 days, survival was significantly greater in the TPE group (92%) than in the SMT group (50%) (p = 0.02). The greatest survival benefit was observed in patients with Grade 4 encephalopathy. The ICU stay was longer in the TPE group, reflecting the complexity of ALF management. Conclusion: TPE significantly improves 30-day survival in ALF patients compared with SMT alone, supporting its role as an adjunct therapy. Further studies are needed to refine patient selection and optimize treatment protocols.

5 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AHAline Huerta
Aline Huerta
MAMariana Arellano
Mariana Arellano
CCClyo Anahí Chávez-Méndez
Clyo Anahí Chávez-Méndez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
CPCarmen Palacios-Reyes
Carmen Palacios-Reyes
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease, linked closely to metabolic syndrome and rising obesity rates. Affecting up to 37% of the global adult population, MASLD prevalence is exceptionally high among individuals of Hispanic descent, with genetic factors such as the PNPLA3 gene mutation playing a significant role. This review focuses on the traditional Mesoamerican "milpa" diet, which includes unprocessed local crops like maize, beans, pumpkins, chili, and tomatoes, and may offer a strategy to combat MASLD. Current treatment recommendations emphasize weight loss, reduced intake of saturated fats, processed meats, and added sugars, and increased physical activity. The milpa diet, rich in protein, fiber, vitamins, and bioactive compounds, aligns with these recommendations and could potentially mitigate MASLD by preventing liver fat accumulation and fibrosis. Additionally, research suggests that coffee consumption may reduce MASLD progression, while alcohol avoidance is crucial. The study concludes that adopting the milpa diet could be a culturally relevant, nutritious, and sustainable dietary approach to preventing and treating MASLD, promoting better liver health and reducing the risk of associated diseases.